GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cutia Therapeutics (HKSE:02487) » Definitions » Net Change in Cash

Cutia Therapeutics (HKSE:02487) Net Change in Cash : HK$-95.1 Mil (TTM As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Cutia Therapeutics Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Cutia Therapeutics's Net Change in Cash for the six months ended in Dec. 2024 was HK$117.0 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2024 was HK$-95.1 Mil.

Cutia Therapeutics Net Change in Cash Historical Data

The historical data trend for Cutia Therapeutics's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cutia Therapeutics Net Change in Cash Chart

Cutia Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Net Change in Cash
-118.82 293.40 7.93 -93.37

Cutia Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Net Change in Cash Get a 7-Day Free Trial -122.65 249.04 -241.11 -212.16 117.04

Cutia Therapeutics Net Change in Cash Calculation

Cutia Therapeutics's Net Change in Cash for the fiscal year that ended in Dec. 2024 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-472.962+337.463+40.403+1.727
=-93.4

Cutia Therapeutics's Net Change in Cash for the quarter that ended in Dec. 2024

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-210.143+291.345+34.7+1.139
=117.0

Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-95.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cutia Therapeutics Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Cutia Therapeutics's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Cutia Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cutia Therapeutics (HKSE:02487) » Definitions » Net Change in Cash
Comparable Companies
HKSE:06996 HKSE:02563 HKSE:02181 HKSE:03681 HKSE:02566 HKSE:01875 HKSE:06978 HKSE:02137 HKSE:01521 HKSE:06998 VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
436 Heng Feng Road, 20th Floor, Huanzhi Building, Jingan District, Shanghai, CHN, 200070
Website
https://www.cutiatx.com
Cutia Therapeutics is a dermatology-focused biopharmaceutical company focused on the broader dermatology treatment and care therapeutic areas, including localized adipose accumulation management medication, scalp diseases and care, skin diseases and care, and topical anesthesia. Its core product is CU-20401, which is a recombinant mutant collagenase that targets obesity, overweight, or other localized adipose accumulation-associated metabolic diseases. Its other products include CU-40102 (topical finasteride spray); CU-10201; CU-40101; and CU-10101 (topical novel small molecule agent) among others. Geographically, the company generates its revenue from the People's Republic of China.
Executives
Zhang Lele 2101 Beneficial owner
Zhang Qiping 2201 Interest of corporation controlled by you
Su Zhou Tong Yu Tou Zi Guan Li He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Su Zhou Tong He Yu Cheng Tou Zi He Huo Qi Ye You Xian He Huo 2101 Beneficial owner
6 Dimensions Capital Gp, Llc 2201 Interest of corporation controlled by you
6 Dimensions Capital, L.p. 2101 Beneficial owner
Su Zhou Yun Zhang Tou Zi Zi Xun You Xian Gong Si 2201 Interest of corporation controlled by you
Yf Dermatology Limited 2101 Beneficial owner
Yunfeng Capital Limited 2102 Investment manager
Yunfeng Fund Iii, L.p. 2201 Interest of corporation controlled by you
Yunfeng Investment Iii, Ltd. 2201 Interest of corporation controlled by you
Pandanus Associates Inc. 2201 Interest of corporation controlled by you
Fil Limited 2201 Interest of corporation controlled by you
Pandanus Partners L.p. 2201 Interest of corporation controlled by you
Hsg Growth V Management, L.p. 2201 Interest of corporation controlled by you

Cutia Therapeutics Headlines

No Headlines